Updates to the PIP Review – What It Means for People with Fibromyalgia
Many people in our community rely on Personal Independence Payment (PIP) to help manage the additional costs of living with fibromyalgia — including travel to medical appointments, heating, mobility aids, and daily living support.
The government has recently expanded the terms of the ongoing PIP review to include current claimants, not just future applicants. This means people already receiving PIP could be affected by any recommendations that result from the review.
For those living with long-term pain, fatigue, and daily challenges, this uncertainty can be especially worrying. PIP is a vital source of stability, independence, and dignity for many.
Why We’re Sharing This
As a charity, Fibromyalgia Friends Together is committed to:
-
Raising awareness of issues affecting people with fibromyalgia
-
Providing clear, reliable information to our community
-
Amplifying the voices and experiences of those with long-term health conditions
-
Supporting efforts that protect essential disability support
Understanding changes to PIP — and how they may affect you — is an important part of that mission.
Have Your Say
Disability-focused organisations are gathering people’s views to ensure the experiences of those who rely on PIP are represented during the review.
One of the questions being asked is whether the government should rule out cuts to PIP for current claimants.
If you would like to share your thoughts, you can take part in the short survey by the Organise Network here:
👉 Share your view on PIP changes
Your response can help highlight why stable, reliable financial support is essential for people managing complex, fluctuating conditions like fibromyalgia.
Why This Matters to Our Community
Fibromyalgia often brings:
-
Chronic pain
-
Fluctuating mobility
-
Fatigue
-
Impact on ability to work
-
Higher daily living costs
Any changes to PIP could have real-world implications for the wellbeing and independence of thousands of people with fibromyalgia across the UK.
We will continue to monitor updates and share information as the review progresses.
